Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Media ReleaseBasel, 7 April 2011Roche announces positive Phase II results for trastuzumab emtansine (T-DM1)in HER2-positiv...
breast cancer.About the TDM4450g studyThe TDM4450g Phase II study is a randomized, multicentre international, two-arm, ope...
majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.All trademarks used or mentioned in th...
Upcoming SlideShare
Loading in …5
×

Positive Phase II results for trastuzumab emtansine (T-DM1)

831 views

Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Positive Phase II results for trastuzumab emtansine (T-DM1)

  1. 1. Media ReleaseBasel, 7 April 2011Roche announces positive Phase II results for trastuzumab emtansine (T-DM1)in HER2-positive metastatic breast cancerRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced topline results of its first randomized trial oftrastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known asTDM4450g, compared trastuzumab emtansine (T-DM1) single agent to the combination of Herceptin(trastuzumab) and chemotherapy (docetaxel) in previously untreated patients. The results showed thatpatients treated with trastuzumab emtansine ( T-DM1 ) in this study lived significantly longer with theirdisease under control (PFS) and experienced fewer side effects typical of chemotherapy.“These encouraging data support our ongoing development program for trastuzumab emtansine (T-DM1) infirst-line HER2-positive metastatic breast cancer,’’ said Hal Barron, M.D., Chief Medical Officer and Headof Global Development. “Trastuzumab emtansine (T-DM1) is a novel treatment with the potential toimprove outcomes for patients with HER2-positive breast cancer due to its efficacy and favourable safetyprofile.”Data from the TDM4450g study will be submitted for presentation at a future medical congress.An earlier analysis of this study presented at the 35th Congress of the European Society of Medical Oncology(ESMO) in 2010i showed encouraging results in tumour shrinkage (overall response rate ORR) in patientswith a minimum of 4 months of follow-up. In addition, the study showed that trastuzumab emtansine (T-DM1) significantly reduced the burden of typical side effects associated with conventional chemotherapy.About Breast CancerBreast cancer is the most common cancer among women worldwide. Each year about 1.4 million new casesof breast cancer are diagnosed worldwide, and over 450,000 people will die of the disease annually. iiIn HER2-positive breast cancer, increased quantities of the HER2 receptor are present on the surface of thetumour cells. This is known as ‘HER2 positivity’ and affects approximately 15-25 percent of women withF. Hoffmann-La Roche Ltd 4070 Basel Group Communications Tel. +41 61 688 88 88 Switzerland Roche Group Media Relations Fax +41 61 688 27 75 www.roche.com 1/3
  2. 2. breast cancer.About the TDM4450g studyThe TDM4450g Phase II study is a randomized, multicentre international, two-arm, open-label clinical trialincluding 137 patients with first-line HER2-positive metastatic breast cancer. Patients from approximately 64sites were randomized to receive either trastuzumab emtansine (T-DM1) or Herceptin and chemotherapy(docetaxel). The primary endpoints of the study were progression-free survival (PFS) and safety. Secondaryendpoints include, objective response, duration of objective response, and clinical benefit rate.About trastuzumab emtansine (T-DM1)Trastuzumab emtansine (the generic, or International Non-proprietary Name for T-DM1) is an antibody-drugconjugate (ADC), being studied for HER2-positive metastatic breast cancer. Due to their targeted nature,ADC s allow for the administration of a highly potent, otherwise intolerable , cytotoxic agent.Because a stable linker is used, the ADC largely remains intact outside the cancer cell, with the cytotoxicagent in an inactive state until it enters the cancer cell, thereby minimising exposure of normal cells to thechemotherapy. The humanized monoclonal antibody (trastuzumab) binds to the HER2-positive cancer cells,and is thought to block out of control signals that contribute to cancer growth and survival while also callingon the body’s immune system to attack the cells. After binding, trastuzumab emtansine (T-DM1) isinternalized into those cancer cells, DM1 containing metabolites of the conjugate specifically destroy thecells.Genentech, a member of the Roche Group, licenses technology for trastuzumab emtansine (T-DM1) underan agreement with ImmunoGen, Inc.About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combinedstrengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with trulydifferentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the worldleader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’spersonalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangibleimprovements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a 2/3
  3. 3. majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.All trademarks used or mentioned in this release are protected by law.Roche Group Media RelationsPhone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com- Alexander Klauser (Head)- Silvia Dobry- Daniel Grotzky- Claudia Schmitt- Annette Walzi E. Perez et al. T-DM1 TDM4450, ESMO 2010, Abstract LBA3ii Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DMGLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet].Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr 3/3

×